Leukotrienes and atherosclerosis - PubMed (original) (raw)
Review
Leukotrienes and atherosclerosis
Graziano Riccioni et al. Curr Drug Targets. 2010 Jul.
Abstract
Evidence from experimental and genetic studies suggest the existence of a potential link between the leukotrienes (LT) signalling cascade, and the pathogenesis/progression of atherosclerosis and its serious consequences such as acute myocardial infarction (AMI), stroke, aortic aneurysms, and intimal hyperplasia. LT biosynthetic enzymes are expressed within atherosclerotic lesion, leading to production of cysteinyl-leukotrienes (Cys-LTs) and LTB4 that exert potent pro-inflammatory action through interaction with CysLT and BLT receptor subtypes expressed on inflammatory and structural cells within the vascular wall. Genetic variants in the genes of the 5-LO pathway have been associated with the risk of developing AMI and stroke. As a result, anti-LT have recently received renewed interest for the treatment of atherosclerosis and its ischemic complications. The aim of this short review is to summarize our current understanding of the role of LTs and their receptors in the genesis and progression of atherosclerosis and review the recent developments on the use of antagonists.
Similar articles
- [Leukotrienes: potential therapeutic targets in cardiovascular diseases].
Bäck M. Bäck M. Bull Acad Natl Med. 2006 Oct;190(7):1511-8; discussion 1518-21. Bull Acad Natl Med. 2006. PMID: 17450683 Review. French. - The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets?
Sharma JN, Mohammed LA. Sharma JN, et al. Inflammopharmacology. 2006 Mar;14(1-2):10-6. doi: 10.1007/s10787-006-1496-6. Inflammopharmacology. 2006. PMID: 16835707 Review. - Leukotriene modifiers in the treatment of cardiovascular diseases.
Riccioni G, Capra V, D'Orazio N, Bucciarelli T, Bazzano LA. Riccioni G, et al. J Leukoc Biol. 2008 Dec;84(6):1374-8. doi: 10.1189/jlb.0808476. Epub 2008 Sep 15. J Leukoc Biol. 2008. PMID: 18794213 Review. - Leukotriene signaling in atherosclerosis and ischemia.
Bäck M. Bäck M. Cardiovasc Drugs Ther. 2009 Feb;23(1):41-8. doi: 10.1007/s10557-008-6140-9. Epub 2008 Oct 24. Cardiovasc Drugs Ther. 2009. PMID: 18949546 Free PMC article. Review. - Inhibitors of the 5-lipoxygenase pathway in atherosclerosis.
Bäck M. Bäck M. Curr Pharm Des. 2009;15(27):3116-32. doi: 10.2174/138161209789058020. Curr Pharm Des. 2009. PMID: 19754386 Review.
Cited by
- Exacerbation of atherosclerosis, hyperlipidemia and inflammation by MK886, an inhibitor of leukotriene biosynthesis, in obese and diabetic mice.
Keever K, Askari B. Keever K, et al. Curr Res Pharmacol Drug Discov. 2024 Oct 10;7:100203. doi: 10.1016/j.crphar.2024.100203. eCollection 2024. Curr Res Pharmacol Drug Discov. 2024. PMID: 39497763 Free PMC article. - Clinical significance of polyunsaturated fatty acids in the prevention of cardiovascular diseases.
Kotlyarov S, Kotlyarova A. Kotlyarov S, et al. Front Nutr. 2022 Oct 6;9:998291. doi: 10.3389/fnut.2022.998291. eCollection 2022. Front Nutr. 2022. PMID: 36276836 Free PMC article. Review. - Eicosanoids in inflammation in the blood and the vessel.
Yamaguchi A, Botta E, Holinstat M. Yamaguchi A, et al. Front Pharmacol. 2022 Sep 27;13:997403. doi: 10.3389/fphar.2022.997403. eCollection 2022. Front Pharmacol. 2022. PMID: 36238558 Free PMC article. Review. - Genetic and Epigenetic Regulation of Lipoxygenase Pathways and Reverse Cholesterol Transport in Atherogenesis.
Kotlyarov S. Kotlyarov S. Genes (Basel). 2022 Aug 18;13(8):1474. doi: 10.3390/genes13081474. Genes (Basel). 2022. PMID: 36011386 Free PMC article. Review. - Molecular Pharmacology of Inflammation Resolution in Atherosclerosis.
Kotlyarov S, Kotlyarova A. Kotlyarov S, et al. Int J Mol Sci. 2022 Apr 27;23(9):4808. doi: 10.3390/ijms23094808. Int J Mol Sci. 2022. PMID: 35563200 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials